Shopping Cart
- Remove All
Your shopping cart is currently empty
PLX5622
🥰Excellent
Catalog No. T7100Cas No. 1303420-67-8
Alias PLX-5622
PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor.
PLX5622
🥰Excellent
Purity: 99.89%
Catalog No. T7100Alias PLX-5622Cas No. 1303420-67-8
PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $97 | In Stock | |
| 10 mg | $161 | In Stock | |
| 25 mg | $324 | In Stock | |
| 50 mg | $537 | In Stock | |
| 100 mg | $649 | In Stock | |
| 500 mg | $1,380 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $86 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PLX5622"
Pexidartinib
Cited
PLX-3397
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.
- $40
Size
QTY
CitedMasitinib
AB1010
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
Sotuletinib Cited
BLZ945
T6119953769-46-5
Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase homologs.
- $31
Size
QTY
CitedGW786034B
Votrient HCl, Pazopanib HCl, GW786034 HCl
T6930635702-64-6
Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
- $48
Size
QTY
Tandutinib
NSC726292, MLN518, CT53518
T1667387867-13-2
Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR, and KDR.
- $38
Size
QTY
GW2580
SC-203877, GW 2580
T2659870483-87-7
GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
- $43
Size
QTY
Linifanib
RG3635, AL-39324, ABT-869
T2514796967-16-3
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
- $43
Size
QTY
Cerdulatinib hydrochloride
PRT2070 hydrochloride, PRT062070 hydrochloride
T61041369761-01-2
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
- $31
Size
QTY
c-Fms-IN-13
T61589885704-58-5In house
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50 = 17 nM) and serves as an anti-inflammatory agent.
- $39
Size
QTY
AZD7507
T143801041852-85-0
AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity.
- $48
Size
QTY
c-Fms-IN-3
T10649885704-21-2In house
c-Fms-IN-3 is a novel inhibitor of c-FMS, suitable for research on antirheumatic and anti-inflammatory diseases.
- $46
Size
QTY
Select Batch
Purity:99.89%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor. |
| Targets&IC50 | CSF1R:Ki: 5.9 nM, CSF1R:0.016 µM (IC50) |
| In vitro | METHODS: CX CR1+/GFP mouse-derived mixed glial cell cultures were treated with PLX5622 (0.1-10 µM) for 7 days and cell counts were assayed by Flow cytometry. RESULTS: Although there was a dose-dependent decrease in microglia numbers under PLX5622, no decrease in GFAP+ astrocytes was seen, but rather a gradual increase, along with a decrease in PDGFR-a OPC. [1] METHODS: Cerebellar sections prepared from PLP-eGFP mouse pups were treated with PLX5622 (1-20 µM) for 3 days followed by Immunostaining. RESULTS: After three days of treatment, PLX5622 at concentrations greater than 2 µM eliminated more than 95% of microglia. [2] |
| In vivo | METHODS: To study in vivo activity, PLX5622 (1200 mg/kg) was administered to PLP eGFP mice by feed for 7-21 days. RESULTS: PLX5622 was effective in depleting microglia in the central nervous system of adult mice. treatment with PLX5622 for 7 days had no effect on oligodendrocyte progenitor cell populations; however, a mild reduction was observed after 21 days in some central nervous system regions. [2] |
| Alias | PLX-5622 |
| Molecular Weight | 395.41 |
| Formula | C21H19F2N5O |
| Cas No. | 1303420-67-8 |
| Smiles | COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1 |
| Relative Density. | 1.364 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||
| Solubility Information | DMSO: 16.67 mg/mL (42.15 mM), Sonication is recommended.  10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.9 mg/mL (19.98 mM), In vivo: Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy PLX5622 | purchase PLX5622 | PLX5622 cost | order PLX5622 | PLX5622 chemical structure | PLX5622 in vivo | PLX5622 in vitro | PLX5622 formula | PLX5622 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.